A detailed history of Bank Of America Corp transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 73,419 shares of GLUE stock, worth $668,847. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73,419
Previous 68,503 7.18%
Holding current value
$668,847
Previous $256,000 51.95%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.59 - $6.97 $17,648 - $34,264
4,916 Added 7.18%
73,419 $389,000
Q2 2024

Aug 14, 2024

BUY
$3.38 - $7.86 $21,611 - $50,256
6,394 Added 10.29%
68,503 $256,000
Q1 2024

May 15, 2024

SELL
$4.26 - $8.46 $79,227 - $157,339
-18,598 Reduced 23.04%
62,109 $437,000
Q4 2023

Feb 14, 2024

SELL
$2.5 - $5.93 $8,387 - $19,895
-3,355 Reduced 3.99%
80,707 $455,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $8.4 $154,654 - $286,776
34,140 Added 68.39%
84,062 $575,000
Q1 2023

May 12, 2023

SELL
$5.95 - $8.21 $173,900 - $239,953
-29,227 Reduced 36.93%
49,922 $388,000
Q4 2022

Feb 10, 2023

SELL
$6.71 - $9.72 $182,364 - $264,170
-27,178 Reduced 25.56%
79,149 $602,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $12.16 $142,776 - $242,142
-19,913 Reduced 15.77%
106,327 $869,000
Q2 2022

Aug 12, 2022

SELL
$6.15 - $14.99 $131,819 - $321,295
-21,434 Reduced 14.51%
126,240 $1.22 Million
Q1 2022

May 16, 2022

BUY
$10.36 - $20.41 $849,706 - $1.67 Million
82,018 Added 124.92%
147,674 $2.07 Million
Q4 2021

Feb 08, 2022

SELL
$16.28 - $27.15 $225,396 - $375,891
-13,845 Reduced 17.41%
65,656 $1.34 Million
Q3 2021

Nov 15, 2021

BUY
$18.59 - $42.21 $1.48 Million - $3.36 Million
79,501 New
79,501 $1.77 Million

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $426M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.